Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 32, Issue 9, Pages 933-937Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2022.2113873
Keywords
Amenamevir; antiviral; helicase-primase; herpes simplex virus; HN0037; HSV-1; HSV-2; IM-250; pritelivir
Categories
Ask authors/readers for more resources
Helicase-primase is an interesting target for therapy of herpes simplex virus infections. Multiple drug candidates have been developed and approved. This article describes the patent portfolio of helicase-primase inhibitors from Phaeno Therapeutics and proposes the structure of their drug candidate HN0037.
Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest for me-too approaches. We describe the opportunities and limitations of the helicase-primase inhibitor patent portfolio from Phaeno Therapeutics and propose the structure of their drug candidate HN0037, which has been in-licensed from Medshine Discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available